510(k) for Endocare's CRYOcare system:
This article was originally published in Clinica
Executive Summary
Endocare has received clearance for its CRYOcare surgical system used to treat benign prostatic hyperplasia. The minimally-invasive two-probe system performs ablations to targeted areas of swollen prostate by using extremely cold temperature to freeze and destroy the prostate's tissue. Studies done by researchers in California have shown that 96% of patients who received this treatment for prostate cancer remained cancer-free three years after treatment.